GSK Reports Results of Trelegy Ellipta in P-III CAPTAIN Study for Asthma

Shots:

• The P-III CAPTAIN study involves assessing of Trelegy Ellipta (FF/UMEC/VI) (100/31.25/25, 100/62.5/25, 200/31.25/25 and 200/62.5/25 mcg) vs Relvar/Breo Ellipta (FF/VI) (100/25 and 200/25 mcg) in 2,436 patients with uncontrolled asthma prior treated with ICS/LABA across 15 countries
• The P-III CAPTAIN study results: met its 1EPs; @24wks. 100/62.5/25mcg vs 200/62.5/25mcg, improvement in lung function & trough FEV1 (110ml &r 92ml); 100/62.5/25 and 200/62.5/25 vs 100/25 and 200/25, 13% reduction in exacerbations
• Trelegy Ellipta (qd) is an inhaler triple therapy of fluticasone furoate/umeclidinium/vilanterol indicated for the maintenance treatment of airflow obstruction in COPD. In 2017, Trelegy Ellipta (100/62.5/25 mcg) has received FDA’s approval for COPD

Click here to read full press release/ article | Ref: GSK | Image: Caixin Global